| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259de1b1b6c5512868ec29379824a1c1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-635 |
| filingDate |
2020-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cab62eaf7907a6ff7b264e2fd5a78dd5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c74de359fc92109e217add06e5bf9fb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c23353685a7084ff0d88fe730636f9bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f62b55e21dcd9db5cbfaf5f29e5bf6cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24b1767401745e62c5cd220271b92a82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33b5455209430b2604a499761a6c7f0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73661855694f6a62026ba28a788f9804 |
| publicationDate |
2021-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11129838-B2 |
| titleOfInvention |
Methods of inhibiting pathological angiogenesis |
| abstract |
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022331345-A1 |
| priorityDate |
2017-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |